Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

Trial Details

NCT ID
NCT06758375
Phase
PHASE2
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Low-dose teclistamab
Locations (sample)
  • Monterrey, Nuevo León, Mexico|25.68435,-100.31721

Key Eligibility Criteria

  • ≥18 years of age.
  • Newly diagnosed multiple myeloma.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.
  • Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →